Opening the Blood Brain Barrier with an Electropermanent Magnet System

Jafari, Sahar; Baum, Ittai; Udalov, O. G.; Lee, Yi-Chien; Rodriguez, Olga; Fricke, Stanley T.; Jafari, Maryam; Amini, Mostafa; Probst, Roland; Tang, Xinyao; Chen, Cheng; Ariando, David; Hevaganinge, Anjana; Mair, Lamar O.; Albanese, Christopher; Weinberg, I.

doi:10.3390/pharmaceutics14071503

Cited by 3 publications

(3 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…TTFields have not been approved for use in pediatric cohorts yet with clinical trials solely focused on adults highlighting its value as a potential treatment with minimal cytotoxicity (114,115). Pulsed electric fields have also been implicated in vitro and in vivo with transiently opening the BBB and may be suitable for enhancing drug bioavailability (116)(117)(118).…”

Section: Tumor Treating Fieldsmentioning

confidence: 99%

Therapeutically targeting the unique disease landscape of pediatric high-grade gliomas

Fernando,

Ahmed,

Williams

2024

Front. Oncol.

View full text Add to dashboard Cite

Pediatric high-grade gliomas (pHGG) are a rare yet devastating malignancy of the central nervous system’s glial support cells, affecting children, adolescents, and young adults. Tumors of the central nervous system account for the leading cause of pediatric mortality of which high-grade gliomas present a significantly grim prognosis. While the past few decades have seen many pediatric cancers experiencing significant improvements in overall survival, the prospect of survival for patients diagnosed with pHGGs has conversely remained unchanged. This can be attributed in part to tumor heterogeneity and the existence of the blood-brain barrier. Advances in discovery research have substantiated the existence of unique subgroups of pHGGs displaying alternate responses to different therapeutics and varying degrees of overall survival. This highlights a necessity to approach discovery research and clinical management of the disease in an alternative subtype-dependent manner. This review covers traditional approaches to the therapeutic management of pHGGs, limitations of such methods and emerging alternatives. Novel mutations which predominate the pHGG landscape are highlighted and the therapeutic potential of targeting them in a subtype specific manner discussed. Collectively, this provides an insight into issues in need of transformative progress which arise during the management of pHGGs.

show abstract

Section: Tumor Treating Fieldsmentioning

confidence: 99%

Therapeutically targeting the unique disease landscape of pediatric high-grade gliomas

Fernando,

Ahmed,

Williams

2024

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…Thus, POH underlies its ability to overcome the obstacles placed by different types of biological barriers and accordingly shape its multifaceted promise in the drug development for cancer therapy [3]. In a novel approach, Jafari et al demonstrated proof-of-principle of a hybrid electropermanent magnets (EPM)-based device for temporarily opening the BBB using both an in vitro cell culture and an in vivo mice model [4]. This technique is useful for safe and effective drug transport across the BBB and can selectively target different parts of the brain by tailoring electrical waveforms [4].…”

mentioning

confidence: 99%

“…In a novel approach, Jafari et al demonstrated proof-of-principle of a hybrid electropermanent magnets (EPM)-based device for temporarily opening the BBB using both an in vitro cell culture and an in vivo mice model [4]. This technique is useful for safe and effective drug transport across the BBB and can selectively target different parts of the brain by tailoring electrical waveforms [4].…”

mentioning

confidence: 99%